Home > Insider Trading > Filing (0000921895-20-000958)

Filing Details

Accession Number:: 0000921895-20-000958
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2020-03-31 18:34:40
Reporting Period:: 2020-03-13

Accepted Time:: 2020-03-31 18:34:40
Original Submission Date:: 2020-03-27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
727510	Enzon Pharmaceuticals Inc.	ENZN	Biological Products, (No Disgnostic Substances) (2836)	222372868

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1265094	Jonathan Couchman	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	Yes	No
1459450	Myrexis, Inc.	600 Fifth Avenue, 2Nd Floor New York NY 10020	No	No	No	Yes
1571659	Xstelos Corp.	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	No	Yes
1737322	Fund Family Couchman	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	Acquisiton	2020-03-13	19,709	$0.14	1,594,232	No	4	P	Indirect	By Xstelos Corp.
Common Stock, $0.01 Par Value	Acquisiton	2020-03-23	2,678	$0.14	2,928	No	4	P	Indirect	By Myrexis, Inc.
Common Stock, $0.01 Par Value	Acquisiton	2020-03-25	469,551	$0.14	472,479	No	4	P	Indirect	By Myrexis, Inc.
Common Stock, $0.01 Par Value	Acquisiton	2020-03-26	160,785	$0.14	633,264	No	4	P	Indirect	By Myrexis, Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Xstelos Corp.
No	4	P	Indirect	By Myrexis, Inc.
No	4	P	Indirect	By Myrexis, Inc.
No	4	P	Indirect	By Myrexis, Inc.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	4,717,666	Direct
Common Stock, $0.01 Par Value	400,000	Indirect	By Couchman Family Fund

Footnotes

This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis" and, together with Mr. Couchman, the Foundation and Xstelos, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.